Abstract: The embodiments described herein relate to chemically and mechanically durable glass compositions and pharmaceutical packaging formed from the same. According to one embodiment, a glass for pharmaceutical packaging includes from about 70 mol. % to about 80 mol. % SiO2; from about 4 mol. % to about 8 mol. % alkaline earth oxide, the alkaline earth oxide comprising MgO and CaO; X mol. % Al2O3, wherein X is from about 4 to about 8; and Y mol. % alkali oxide comprising non-zero amounts of Na2O and K2O, wherein Y is about 9-15 mol. % and a ratio of Y:X is greater than 1.

Abstract: A gas barrier material includes an atomic sheet, such as graphene and/or an analog of graphene. The gas barrier material can be arranged as part of a component, such as a container or other vessel, to limit the flow or permeation of gas through the component. Where the component is a container or part of a container, the gas barrier material may be formulated and arranged to limit or prevent gas ingress or egress with respect to the internal volume of the container. The atomic sheet offers improved gas barrier properties compared to traditional polymeric barrier materials and is particularly useful in applications where it is desired to limit permeation of small gas molecules such as helium, such as airships or other lighter than air vehicles.

Abstract: Electrical equipment that includes a cabinet comprising a plurality of walls is provided. The cabinet is disposed around a plurality of electric components such as conductors. Further, the electrical equipment also includes at least one barrier. The barrier is disposed in the cabinet and spaced apart from the conductor by a spacing distance to define a channel within the cabinet for air to flow between the barrier and the conductor. The barrier is placed such that a portion of the barrier is coupled to one of the plurality of walls of the electric cabinets.

Abstract: Enhancing dynamic code. A method includes obtaining one or more first data structures defining constructs in a body of dynamic language source code. From the one or more first data structures, identifier information is extracted for one or more of the defined constructs. Knowledge about the constructs is augmented. Using the identifier information and augmented knowledge, metadata about the body of the dynamic language source code is generated. The generated metadata is represented as a symbol table. The body of dynamic language source code is visually enhanced based on the symbol table structure.

Abstract: Methods of fabricating solar cell emitter regions using silicon nano-particles and the resulting solar cells are described. In an example, a method of fabricating an emitter region of a solar cell includes forming a region of doped silicon nano-particles above a dielectric layer disposed above a surface of a substrate of the solar cell. A layer of silicon is formed on the region of doped silicon nano-particles. At least a portion of the layer of silicon is mixed with at least a portion of the region of doped silicon nano-particles to form a doped polycrystalline silicon layer disposed on the dielectric layer.

Abstract: The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, LEVEMIR, NOVOLOG, NOVOLIN 70-30, NOVOLIN R, NOVOLIN N, NOVOLOG MIX 70-30 and NOVOLIN L.

Abstract: A packaging system for radioactive waste is robust, highly functional, and can be used for nearly all radioactive waste streams that require shielded packaging. The packaging system includes a modular container that is configured to receive modular shielding inserts. The packaging system can be used to store, transport, and dispose of radioactive waste.

Abstract: Mobile protocol packets, with a header field and a payload field, are communicated from a user mobile equipment to an application-aware serving gateway. The application-aware mobile protocol serving gateway detects header information in the header field and application information in the payload field to manage the mobile protocol packets based on a policy.

Abstract: The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, NEUPOGEN (filgrastim), NEULASTA (pegfilgrastim), EPOGEN (epoetin alfa) or ENBREL (etanercept).

Abstract: Methods of making personal care compositions including microcapsules and methods of enhancing the efficacy of the microcapsules in said personal care compositions.

Abstract: Methods of making personal care compositions including microcapsules and methods of enhancing the efficacy of the microcapsules in said personal care compositions.

Abstract: A prosthetic device including a proximal ring having a plurality of proximal ring openings, a means for securing an object in the proximal ring openings, a distal ring having a plurality of distal ring openings, a means for securing an object in the distal ring openings, and a plurality of rods each having a proximal end and a distal end. The proximal end of each of the plurality of rods is adapted to be received in one of the plurality of proximal ring openings, the distal end of each of the plurality of rods is adapted to be received in one of the plurality of distal ring openings, and at least one of the proximal ring and the distal ring is adjustably attached to the rods. The method includes adjusting the prosthetic device by moving the proximal ring and/or the distal ring relative to at least one of the rods.

Abstract: The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient.

Abstract: A method of fabricating a solar cell is disclosed. The method includes forming a polished surface on a silicon substrate and forming a first flowable matrix in an interdigitated pattern on the polished surface, where the polished surface allows the first flowable matrix to form an interdigitated pattern comprising features of uniform thickness and width. In an embodiment, the method includes forming the silicon substrate using a method such as, but not limited to, of diamond wire or slurry wafering processes. In another embodiment, the method includes forming the polished surface on the silicon substrate using a chemical etchant such as, but not limited to, sulfuric acid (H2SO4), acetic acid (CH3COOH), nitric acid (HNO3), hydrofluoric acid (HF) or phosphoric acid (H3PO4). In still another embodiment, the etchant is an isotropic etchant. In yet another embodiment, the method includes providing a surface of the silicon substrate with at most 500 nanometer peak-to-valley roughness.

Abstract: Coated pharmaceutical packages are disclosed. In embodiments, a coated pharmaceutical package may include a glass body comprising a first surface. A low-friction coating may be positioned on at least a portion of the first surface of the glass body. The low-friction coating may include a polymer chemical composition. The coated pharmaceutical package may be thermally stable at a temperature of at least about 260° C. for 30 minutes. The low-friction coating may have a mass loss of less than about 5% of its mass when heated from a temperature of 150° C. to 350° C. at a ramp rate of about 10° C./minute.

Abstract: Electrical power load data is obtained for a power consumption facility for a period of time of at least one year. A load duration curve is created for the power consumption facility for the period of time based on the electrical power load data. Anticipated electrical power production data is obtained for an inverter-based power generator for the period of time. A power generation curve is created for the inverter-based power generator for the period of time. The power generation curve is evaluated against the load duration curve to determine a required electrical power supply capacity and duration for an electrical storage system to cover peak power demand of the power consumption facility. An energy storage technology and configuration of the electrical storage system is determined for satisfying required electrical power supply capacity and duration for the electrical storage system to cover peak power demand of the power consumption facility.

Abstract: The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, NEUPOGEN® (filgrastim), NEULASTA® (pegfilgrastim), (epoetin alfa) or ENBREL® (etanercept).

Abstract: Coated pharmaceutical packages are disclosed. In embodiments, a coated pharmaceutical package includes a glass body comprising a first surface. A low-friction coating may be positioned on at least a portion of the first surface of the glass body. The low-friction coating may include a polymer chemical composition. A light transmission through the coated pharmaceutical package may be greater than or equal to about 55% of a light transmission through an uncoated pharmaceutical package for wavelengths from about 400 nm to about 700 nm. The low-friction coating may have a mass loss of less than about 5% of its mass when heated from a temperature of 150° C. to 350° C. at a ramp rate of about 10° C./minute.

Abstract: Spray drying microcapsules with particulates, the microcapsules that result from such spray drying, and compositions and methods of making said compositions including the spray-dried microcapsules.

Abstract: The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, LANTUS (insulin glargine [rDNA]), LOVENOX (Enoxaparin), PENTACT-HIB (Hemophilus influenzae type b polysaccharide conjugated to tetanus protein, diphtheria, tetanus, pertussis and inactivated poliovirus vaccines) or FLUZONE or VAXIGRIP (influenza virus vaccine).